Oncology Medical News about Multiple myeloma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Multiple myeloma
The Lancet - Early Online Publication, 06/24/09

Raab MS et al. - In a review of multiple myeloma (MM), it was concluded that although benefit was first shown in relapsed and refractory disease, improved overall response, duration of response, and progression-free and overall survival can be achieved when these drugs are part of first-line regimens.

Methods

MM is characterised by clonal proliferation of malignant plasma cells.
Mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis.

Results

This knowledge has already expanded treatment options for pts with MM.
Prototypic drugs thalidomide, bortezomib, and lenalidomide have each been approved for treatment of MM by targeting both multiple myeloma cells and bone marrow microenvironment.
This treatment framework promises to improve outcome not only for pts with MM, but also with other haematological malignancies and solid tumours.

<< Previous
Thyroid tumours of uncertain malignant potential: frequency and...

Next >>
Wilms tumor 1 gene mutations are associated with a higher risk of...